[18F]-DPA-714 トリプルネガティブ乳がんにおける PET/CT (陽電子放出断層撮影/コンピュータ断層撮影) (EITHICS)
パイロット実現可能性研究: トリプルネガティブ乳がんにおける [18F]-DPA-714 PET/CT による M2 マクロファージ探索の炎症と存在
This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The purpose of this study is to evaluate the correlation of inflammation assessed by M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F] DPA-714 PET imaging by using qualitative and image texture analysis in patients with triple negative breast cancer.
Patients receive pre-therapeutic diffusion-weighted breast MRI (Magnetic resonance imaging) and 18FDG (fluorodeoxyglucose) PET/CT (Positron Emission Tomography/Computerized Tomography) scan within 30 days before enrollment.
[18F] DPA-714 PET/CT scan is performed before surgery. About 3 MBq/Kg of [18F] DPA-714 are injected intravenously, two acquisition sequences are performed following injection and 60 minutes after injection in order to evaluate early and late tumor uptake of [18F] DPA-714.
Surgery is scheduled after [18F] DPA-714 PET/CT scan. Tissue samples from breast surgery are used to assess M1 and M2 macrophages expression and to perform tumor molecular subtyping by Immunohistochemical analysis. Tumor Autoradiography with the TSPO (18 kDa Translocator Protein) ligand [18F]DPA-714 will be also assessed on tumor tissue.
A blood sample is performed before [18F] DPA-714 PET/CT scan in order to assess the genotyping of TSPO (18 kDa Translocator Protein) gene.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Paris、フランス、75020
- APHP - Hôpital Tenon
-
Saint-Herblain、フランス、44805
- Institut de cancerologie de l'Ouest
-
Tours、フランス、37044
- CHU Bretonneau
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
18 Years and older
-
Triple negative primary breast cancer based on immunohistochemical results as follows:
- Estrogen receptor < 10%
- And Progesterone receptors < 10%
- And HER2 (Human Epidermal Growth Factor Receptor-2) not amplified or not overexpressed
-
Patient with a primary tumor eligible for primary surgery
-
Performance Status equal to 0 or 1
-
Fertile patients must use effective contraception
-
Patient must be affiliated to a Social Health Insurance
-
Written informed consent
Exclusion Criteria:
- Patient with No triple negative breast cancer
- Patient with inflammatory breast cancer
- Patient with metastatic breast cancer
- Patient receiving cancer treatments such as chemotherapy, immunotherapy, biologic response modifiers, hormonal therapy, and radiotherapy BEFORE the biopsy and PET scans are performed
- Treated diabetes with fasting blood glucose > 10 mmol/L
- Patient who received antibiotics and/or steroidal and/or non-steroidal anti-inflammatory drugs within 30 days PRIOR to [18F]-DPA-714 PET scan
- Contraindication to MRI (implants or metallic prosthesis, severe claustrophobia, pacemaker ...)
- Patient deprived of liberty, under a measure of safeguard of justice, under guardianship or under the authority of a guardian
- Pregnant or nursing patient
- Agitation; impossibility of lying motionless for at least 1 hour, or known claustrophobia
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:[18F]-DPA-714 PET/CT
[18F]-DPA-714 PET/CT scan |
[18F]-DPA-714 |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Predominance of M2-Polarized Macrophages
時間枠:2 months
|
Intratumoral macrophages were quantified by immunohistochemistry on surgical tumor specimens. CD68-positive cells were used to quantify the total macrophage population (M1 and M2 macrophages), whereas CD163-positive cells were used to identify M2-polarized macrophages. The percentage of M2 macrophages was calculated as the proportion of CD163-positive cells among all CD68-positive macrophages. Results are presented as the number of participants whose tumors showed a predominance of M2-polarized macrophages. |
2 months
|
|
Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT
時間枠:2 months
|
The correlation between the percentage of CD163-positive M2 macrophages (determined by immunohistochemistry) and tumor SUVmax on [18F]DPA-714 PET/CT was assessed using Spearman's rank correlation coefficient. |
2 months
|
|
Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT
時間枠:2 months
|
The correlation between intratumoral CD68-positive macrophage infiltration (assessed by immunohistochemistry) and tumor SUVmax on [18F]DPA-714 PET/CT was evaluated using Spearman's rank correlation coefficient. |
2 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Distribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO Genotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder)
時間枠:2 months
|
Tumor uptake patterns were classified as above, equal to, or below muscular background and are presented descriptively according to TSPO genotype (HAB, MAB, LAB). No formal statistical analysis was performed because of the limited sample size. |
2 months
|
|
Slope of Tumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT Acquisition
時間枠:1 month
|
Early tumor uptake was assessed using dynamic PET/CT time-activity curves (TACs). Results are presented as the slope of tracer accumulation derived from tumor TACs. Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. |
1 month
|
|
Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI
時間枠:1 month
|
Primary tumor detection was assessed qualitatively using [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and diffusion-weighted breast MRI. Results are presented as the number of participants in whom the primary tumor was identified by each imaging modality. |
1 month
|
|
[18F]-DPA-714 Toxicity
時間枠:1 month
|
Number of patients with adverse events and serious adverse event after [18F]-DPA-714 administration |
1 month
|
|
Tumor SUVmean During Late [18F]-DPA-714 PET/CT Acquisition
時間枠:1 month
|
Late tumor uptake was assessed during the plateau phase of dynamic [18F]-DPA-714 PET/CT time-activity curves (TACs). Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. Results are presented as median SUVmean values and ranges for each uptake pattern. |
1 month
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Caroline ROUSSEAU, MD, PhD、Institut de Cancerologie de l'Ouest
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ICO-N-2019-04
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。